Analytical Data
-
Gene name
Latent TGF beta 1/TGFB1
- Application
-
Alternative Names
Transforming growth factor beta-1 proprotein [Cleaved into: Latency-associated peptide(LAP); Transforming growth factor beta-1(TGF-beta-1)]
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P04202
-
Expression Region
279-390aa
-
Molecular Weight
16.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Latent TGF-beta 1 (Transforming Growth Factor-beta 1) is a crucial cytokine involved in various physiological processes, including cell proliferation, differentiation, and immune regulation. In its latent form, TGF-beta 1 is sequestered in the extracellular matrix, where it remains inactive until specific activation occurs. This regulation is vital since dysregulated TGF-beta signaling has been implicated in a range of pathologies, including fibrosis, cancer, and autoimmune diseases. The study of recombinant latent TGF-beta 1/TGFB1 proteins has gained traction in recent years, as they provide an essential tool for understanding the mechanisms of TGF-beta activation and its downstream effects. Researchers aim to characterize the molecular interactions that stabilize the latent form and the signals that promote its activation. Furthermore, the development of therapeutic strategies targeting TGF-beta pathways could offer potential interventions for diseases characterized by excessive TGF-beta signaling. By better understanding the biology of latent TGF-beta 1, scientists hope to uncover novel insights into its role in health and disease, paving the way for innovative therapeutic approaches.
